189,224 Shares in Phibro Animal Health Corporation $PAHC Acquired by Globeflex Capital L P

Globeflex Capital L P acquired a new stake in Phibro Animal Health Corporation (NASDAQ:PAHC) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 189,224 shares of the company’s stock, valued at approximately $5,942,000. Globeflex Capital L P owned approximately 0.47% of Phibro Animal Health at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. 1620 Investment Advisors Inc. grew its stake in shares of Phibro Animal Health by 77.4% in the fourth quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after purchasing an additional 386 shares in the last quarter. KBC Group NV acquired a new stake in Phibro Animal Health in the 1st quarter worth about $29,000. Rothschild Investment LLC boosted its holdings in Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock valued at $39,000 after purchasing an additional 1,000 shares during the period. Finally, iSAM Funds UK Ltd acquired a new position in shares of Phibro Animal Health during the 3rd quarter worth approximately $61,000. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Stock Performance

Shares of NASDAQ:PAHC opened at $36.32 on Monday. The company’s 50 day simple moving average is $33.70 and its 200 day simple moving average is $42.61. The stock has a market capitalization of $1.47 billion, a price-to-earnings ratio of 15.59, a price-to-earnings-growth ratio of 0.51 and a beta of 0.46. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. Phibro Animal Health Corporation has a 1 year low of $28.25 and a 1 year high of $60.08.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Wednesday, September 2nd will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio (DPR) is currently 20.60%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PAHC. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Citigroup reduced their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a report on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $42.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.